Australia’s CellAED defibrillator failures and regulatory loopholes
Consensus Summary
The CellAED, a smartphone-sized defibrillator approved in Australia in 2021, became the focus of a deadly regulatory failure after a married couple used it on their elderly neighbor in November [DATE UNVERIFIED]. The device delivered a shock after a 50-second delay, shocking the pregnant wife as well, and the neighbor died shortly after paramedics arrived. Despite over 23,000 units sold or donated in Australia, including to ambulance services, the CellAED lacked human clinical evidence to prove its effectiveness. The UK regulator withdrew its certification in 2024 after finding major safety failures, including sparking, burning, and inadequate clinical data. The TGA, Australia’s medical device regulator, was aware of these concerns since 2023 but allowed the device to remain registered until February [DATE UNVERIFIED], when the manufacturer canceled its own registration. The device’s low shock power (85 joules vs. recommended 200 joules) and lack of proper testing contributed to its failures, including 22 adverse event reports, six of which involved deaths in 2023. While some users reported success, studies and expert opinions suggest the device’s risks outweighed its benefits, highlighting systemic flaws in Australia’s medical device approval process.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- The CellAED was approved in Australia in 2021 without human clinical evidence proving it could save lives.
- More than 23,000 CellAED units were sold or donated in Australia, including to Ambulance Victoria and Canberra ambulance services.
- Ambulance Victoria equipped over 700 community volunteers with CellAED devices.
- The UK regulator withdrew the CellAED’s certification in 2024 after finding major safety failures, including sparking, burning, and lack of clinical data.
- The CellAED generates only 85 joules, well below the 200 joules recommended by standards.
- The TGA received 22 adverse event reports about the CellAED, including six complaints in 2023 where the device failed to shock patients during cardiac arrest, resulting in death.
- The CellAED was the subject of four Class 1 recalls (highest risk level) in Australia since 2023, including one for devices that failed to shock during testing but were sent to customers.
- A study in the journal *Resuscitation Plus* found no evidence that ultra-portable defibrillators like the CellAED work.
- The CellAED was withdrawn from the UK market more than a year before the Australian incident, after regulators raised safety concerns.
- The CellAED costs $599 and is the size of a smartphone, compared to standard defibrillators which cost more and are bulkier.
Points of Difference
Details reported by only one source:
- The CellAED was approved by a private German assessor, and the TGA rubber-stamped it without assessing clinical evidence.
- The UK’s British Standards Institution found the CellAED’s clinical evaluation did not follow ‘commonly accepted scientific methods’ and relied on a pig study, not human data.
- A man in France died after responders used a CellAED with English instructions instead of translated ones during a motorcycle accident.
- Rapid Response Revival (RRR) Manufacturing issued a statement claiming it provided clinical trial data and real-world use cases showing no safety issues, but withdrew the device commercially in the UK.
- The CellAED was dreamt up by entrepreneur Donovan ‘Donno’ Casey, who nearly lost his wife to cardiac arrest and raised over $60 million from investors.
- No additional unique details beyond SMH.
Contradictions
Conflicting information between sources:
- The articles do not provide any conflicting information; all factual claims are consistent between sources.
Source Articles
Sparking, burning and a 50-second delay: The deadly loophole in Australia’s medical device rules
It was hailed as a homegrown tech triumph. But an exclusive analysis of regulatory reports exposes how our system put the flawed defibrillator into Australian hands.
Sparking, burning and a 50-second delay: The deadly loophole in Australia’s medical device rules
It was hailed as a homegrown tech triumph. But an exclusive analysis of regulatory reports exposes how our system put the flawed defibrillator into Australian hands.